EQS-News: Viromed Medical AG enters into a distribution partnership with TriPart for the market launch of ViroCAP® and PulmoPlas® in Turkey

Viromed Medical AG enters into a distribution partnership with TriPart for the market launch of ViroCAP® and PulmoPlas® in Turkey

Pinneberg, 24 July 2025 – Viromed Medical AG (Viromed; ISIN: DE000A3MQR65), a medical technology company and a pioneer in cold plasma technology, has entered into a new distribution partnership with TriPart TITAN GmbH & Co. KG, a company specializing in the marketing of medical devices and technology. The agreement facilitates the market entry of the new Viromed products ViroCAP® and PulmoPlas® in Turkey. These innovative medical technology products are set to launch in the first quarter of 2026.

As part of the collaboration, an initial 5,000 units of the ViroCAP® – a mobile medical device for the treatment of skin diseases using cold atmospheric plasma – are to be procured. The agreement also covers 750 PulmoPlas® units, which are medical devices for preventing and treating ventilator-associated pneumonia (VAP) in mechanically ventilated patients using cold atmospheric plasma. The products are intended for use in hospitals and by general practitioners as well as surgical specialists. Distribution is on a prepayment basis, with no fixed advance payments agreed contractually.

Uwe Perbandt, the CEO of Viromed Medical AG: “With TriPart, we have gained a strong partner with direct access to medical facilities and decision-makers in the Turkish healthcare sector. Turkey is a strategically important growth market for us, with a population of almost 90 million, and highly relevant to our international expansion goals.” This distribution agreement marks another step in the implementation of the company's dynamic growth phase.

In parallel with the planned market launch in Turkey, Viromed has commissioned its technology partner, relyon plasma GmbH, a subsidiary of TDK Electronics AG, to produce 11,000 ViroCAP® devices for delivery in 2026. These will be used to supply new international markets and ensure availability for existing distribution partnerships, among other things.

Viromed already has numerous sales and marketing partnerships in place: The exclusive distribution agreement with the Korean company UMECO covers ten Asian countries. The partnership with Lang Life Sciences GmbH targets the veterinary medicine market.

About Viromed Medical AG
Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

Contact Viromed
E-Mail: kontakt@viromed-medical.de
 

Press contact
E-Mail: viromed@kirchhoff.de